Riomet is a drug owned by Ranbaxy Signature Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 14, 2023. Details of Riomet's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6890957 | Liquid formulation of metformin |
Sep, 2023
(1 year, 3 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Riomet's patents.
Latest Legal Activities on Riomet's Patents
Given below is the list of recent legal activities going on the following patents of Riomet.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail-Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 25 May, 2007 | US6890957 |
| Petition Entered | 29 Jan, 2007 | US6890957 |
| Post Issue Communication - Certificate of Correction Denied | 14 Dec, 2006 | US6890957 |
| Post Issue Communication - Certificate of Correction | 17 Aug, 2005 | US6890957 |
| Patent Issue Date Used in PTA Calculation Critical | 10 May, 2005 | US6890957 |
| Recordation of Patent Grant Mailed Critical | 10 May, 2005 | US6890957 |
| Issue Notification Mailed Critical | 20 Apr, 2005 | US6890957 |
| Receipt into Pubs | 14 Apr, 2005 | US6890957 |
| Dispatch to FDC | 13 Apr, 2005 | US6890957 |
| Application Is Considered Ready for Issue Critical | 13 Apr, 2005 | US6890957 |
US patents provide insights into the exclusivity only within the United States, but Riomet is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Riomet's family patents as well as insights into ongoing legal events on those patents.
Riomet's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Riomet's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 14, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Riomet Generic API suppliers:
Metformin Hydrochloride is the generic name for the brand Riomet. 68 different companies have already filed for the generic of Riomet, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Riomet's generic
How can I launch a generic of Riomet before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Riomet's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Riomet's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Riomet -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 500 mg/5 mL | 02 Feb, 2018 | 1 | 03 Mar, 2020 | 07 Aug, 2021 | Eligible |
Alternative Brands for Riomet
There are several other brand drugs using the same active ingredient (Metformin Hydrochloride) as Riomet. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||||
|---|---|---|---|---|---|---|
| Andrx Labs Llc |
| |||||
| Astrazeneca Ab |
| |||||
| Boehringer Ingelheim |
| |||||
| Bristol Myers Squibb |
| |||||
| Emd Serono Inc |
| |||||
| Janssen Pharms |
| |||||
| Msd Sub Merck |
| |||||
| Novo Nordisk Inc |
| |||||
| Santarus Inc |
| |||||
| Sb Pharmco |
| |||||
| Sun Pharm |
| |||||
| Takeda Pharms Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Metformin Hydrochloride, Riomet's active ingredient. Check the complete list of approved generic manufacturers for Riomet
About Riomet
Riomet is a drug owned by Ranbaxy Signature Llc. Riomet uses Metformin Hydrochloride as an active ingredient. Riomet was launched by Ranbaxy in 2003.
Approval Date:
Riomet was approved by FDA for market use on 11 September, 2003.
Active Ingredient:
Riomet uses Metformin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Metformin Hydrochloride ingredient
Dosage:
Riomet is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG/5ML | SOLUTION | Discontinued | ORAL |